Indicated for treatment of Aspergillus species, Candida species, and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or if renal impairment or unacceptable toxicity precludes use of amphotericin B deoxycholate
Liposomal formulations have been found to have less renal toxicity than deoxycholate,and fewer infusion-related reactions. They are more expensive than amphotericin B deoxycholate.